Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C6H5O7.3Mn.10H2O |
Molecular Weight | 723.1663 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.O.O.O.O.[Mn++].[Mn++].[Mn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=ZOLZOTLXESSOMN-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Mn.10H2O/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;;;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;10*1H2/q;;3*+2;;;;;;;;;;/p-6
DescriptionSources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Sources: https://www.alfa.com/en/catalog/032808/https://www.ncbi.nlm.nih.gov/pubmed/6658791https://www.ncbi.nlm.nih.gov/pubmed/3725729 | https://www.ncbi.nlm.nih.gov/pubmed/3989083 | https://www.ncbi.nlm.nih.gov/pubmed/25464291 | https://www.ncbi.nlm.nih.gov/pubmed/20934746https://google.com/patents/CN104529454A?http://pubs.acs.org/doi/pdfplus/10.1021/jo970656jhttps://www.drugs.com/pro/manganese-sulfate-injection.htmlhttp://www.druginfosys.com/drug.aspx?drugcode=2295&type=1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=184 | https://www.ncbi.nlm.nih.gov/pubmed/24861367
Curator's Comment: description was created based on several sources, including
https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm
Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).
Originator
Sources: https://www.americanelements.com/manganese-ii-iodide-7790-33-2https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19610920&CC=GB&NR=877677A&KC=Ahttp://www.newworldencyclopedia.org/entry/Manganese
Curator's Comment: Manganese was first discovered by Torbern Olof Bergman in 1770 and first isolated by Johann Gottlieb Gahn in 1774.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075097 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19032027 |
|||
Target ID: CHEMBL1795148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25974698 |
|||
Target ID: CHEMBL4612 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25974698 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseManganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese. |
|||
Primary | Unknown Approved UseManganese is used for weak bones (osteoporosis). |
|||
Palliative | Unknown Approved UseEarly research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension. |
|||
Curative | MANGANESE SULFATE Approved UseManganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
Primary | MANGANESE SULFATE Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cytochrome oxidase determination using a manganese citrate complex. | 1970 |
|
Dietary calcium and manganese effects on menstrual cycle symptoms. | 1993 May |
|
Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions. | 2001 Jun 18 |
|
Differential ability of transition metals to induce pulmonary inflammation. | 2001 Nov 15 |
|
Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative? | 2002 Jul 31 |
|
Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. | 2005 Mar |
|
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats. | 2016 Nov |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 184.1449
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1791698
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
ALTERNATIVE | |||
|
DB14495
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
4Z2OA6A13N
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
4Z2OA6A13N
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
300000030951
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
96030-94-3
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
283767
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
71587363
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
DTXSID60242101
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY | |||
|
SUB14469MIG
Created by
admin on Fri Dec 15 15:07:12 GMT 2023 , Edited by admin on Fri Dec 15 15:07:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD